Biocon wins USFDA approval for generic weight-loss drug Liraglutide
Biocon wins USFDA approval for generic weight-loss drug Liraglutide is drawing significant interest across the industry.
Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- What SAG Awards insiders really think of the Warner Bros. deal
- Noisy humans harm birds and affect breeding success: study
- Snoop Dogg goes from Winter Olympics role to visiting new soccer love Swansea
- Apple updates the iPad Air with an M4 chip
Source: Original →